RxDoctor Payments Data

James Surdy, MD

Internal Medicine · Hallock, MNNPI 1083705206

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $78 and has fallen 55.3% since, to $35 in 2025.

$178in general payments, 2019–2025

Across 10 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$39
  • Corium, LLC$32
  • Abbott$24
  • Pharmacosmos Therapeutics Inc.$21
  • E.r. Squibb & Sons, L.L.C.$18
  • Merck$15
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$178100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$178 in reported general payments places this provider in the 85th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$3,863
Medicare patients
13
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$161,409
RybelsusSemaglutide55$65,126
OzempicSemaglutide58$56,046
JardianceEmpagliflozin42$34,386
MounjaroTirzepatide22$25,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,886
MyrbetriqMirabegron70$21,561
XareltoRivaroxaban22$17,992
FarxigaDapagliflozin Propanediol21$13,698
AbrysvoRsv Vacc, Pref A And Pref B/Pf30$9,278
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,526
DapagliflozinDapagliflozin Propanediol12$6,389
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,403
Rosuvastatin Calcium369$4,331
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$15$25,43322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in Hallock

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →